PhD in Rechtswissenschaften und Health Policy (laufend)
BSc Gesundheitswissenschaften und Technologie, ETH Zürich
LLM, Universität von Kalifornien, Berkeley
MLaw in Rechtswissenschaften, Universität Zürich
BLaw, Universität Genf
Studien:
Vokinger KN, Serra-Burriel M, Glaus CEG, Rohr UP, Hwang TJ, Dalla Torre di Sanguinetto S, Kesselheim AS. Regulatory review duration and differences in submission times of drugs in the United States and in Europe, 2011 to 2020. Annals of Internal Medicine 2023;176(10):1413-1418. Link
Vokinger KN, Glaus C, Kesselheim AS, Serra-Burriel M, Ross JS, Hwang TJ. Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study. The British Medical Journal (BMJ) 2023;382:e074166. Link
Glaus CEG, Kloeti A, Vokinger KN. Defining "therapeutic value" of medicines: a scoping review. BMJ Open 2023;13e078134. DOI: 10.1136/bmjopen-2023-078134. Link
Vokinger KN, Glaus CEG, Kesselheim AS. Approval and therapeutic value of gene therapies in the US and Europe. Gene Therapy 2023. DOI: https://doi.org/10.1038/s41434-023-00402-4. Link
Vokinger KN, Kesselheim AS, Glaus, CEG, Hwang TJ. Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe from 2007 to 2021. JAMA Health Forum 2022;3(8):e222685. Link
Vokinger KN, Hwang TJ, Glaus CEG, Kesselheim AS. Therapeutic value assessments of novel medicines in the US and Europe, 2018-2019. JAMA Network Open 2022;5(4):e226479. Link
